Articles tagged with Antigens
A recent study found that stress increases anxiety and depression scores in college students with mild allergic asthma, leading to enhanced airway inflammation. In contrast, intravenous sildenafil reversed vascular resistance in an animal model of neonatal pulmonary hypertension, offering new hope for treating this serious condition.
Researchers have determined the mechanism that draws immune system's B cells toward T cells, needed to launch an antibody response after exposure to foreign antigen. The discovery highlights the role of chemokine receptors in guiding B cell movement, which may underlie a range of cellular movements in embryonic development.
The new antigen microarrays can diagnose diseases on the first visit, enabling clinicians to pinpoint specific antigens under attack in autoimmune diseases. The arrays also aid in designing effective treatments tailored to individual patients, bypassing the entire immune system.
The study reveals key mechanisms and pathways involved in immune response regulation. It highlights the importance of understanding immunological functions to develop new therapeutic approaches.
Studies found that agnoprotein and T antigen are present in 45% of medulloblastoma samples, with some containing only agnoprotein. The presence of these proteins suggests a potential link between the JC virus and brain tumor development.
Researchers found viral genome and proteins T antigen and agnoprotein in pediatric brain tumor samples, suggesting a potential role in tumor development. The discovery of agnoprotein expression in the absence of T-antigen expression suggests a possible pathway for tumor growth.
Scientists have identified ILT3 and ILT4, a key pair of molecules that function as a brake for the immune response. Increasing their activity on dendritic cells may create tolerance to foreign tissues, while decreasing it can enhance the immune response against malignant cells.
Researchers at the University of Pittsburgh Medical Center have identified cyclin B1 as a promising new tumor antigen for cancer vaccine development. The study found that cyclin B1 is over-expressed in breast and lung cancer cells, making it an attractive target for immunotherapy.
Researchers at Ohio State University have developed a new DNA-based vaccine approach that successfully immunizes mice against anthrax. The vaccine uses combinations of two gene products produced by the bacteria responsible for causing anthrax, resulting in strong immune responses.
A new DNA-based cancer treatment has shown promise by targeting and eliminating tumor cells. Researchers have discovered that DNA vaccination can place tumors in a state of immune activation, making them more susceptible to attack.
The Office of Naval Research developed an inexpensive and effective HLA test to screen potential bone marrow donors, increasing compatibility by 30%. New research aims to slow down tissue rejection response, allowing near matches.
The Sequella Global Tuberculosis Foundation has awarded $500,000 in grants to nine researchers working on innovative tuberculosis vaccines. The grants will fund projects using novel adjuvants, delivery mechanisms, and immunological approaches.
Researchers at Dendreon Corporation have developed a method for generating enhanced immune responses with potentially important implications for therapeutic cancer vaccines. The approach involves modifying antigens to optimize uptake and processing by dendritic cells, resulting in significant cytotoxic T-cell activity.
Researchers at Duke University Medical Center and Geron Corp. have made promising findings on a 'universal' cancer vaccine based on the telomerase protein. The active part of telomerase can stimulate development of immune cells that recognize and kill multiple, unrelated mouse and human cancer cells.
Researchers at National Jewish Health discovered how proteins IL-15 and IL-2 work together to control the immune response against viruses. The proteins balance the production and division of memory killer T cells, allowing the immune system to battle antigens with a controlled response.
Using genetically manipulated T cells producing a fluorescent jellyfish protein, researchers observed the movement of MEKK2 towards T cell receptors within seconds of antigen binding. This study reveals MEKK2's crucial role in delivering molecular signals to the nucleus and active attachment between immune cells.
Researchers used imaging to 'movie' the interaction between a T cell and an antigen-presenting cell, revealing specific protein rearrangements that form an immunological synapse. This structure determines whether a T cell will respond to an antigen.
The study identifies a mechanism by which the immune system eliminates dysfunctional T cells, which can lead to autoimmune diseases and cancer. The research suggests that continuous contact with class I MHC proteins is essential for maintaining the balance between cell survival and death.
Roy Curtiss III's patent covers a genetically engineered bacterial antigen delivery system that induces immune responses against foreign antigens. The technology is being used to develop recombinant vaccines for various pathogens, including Heliobacter pylori and Mycobacterium tuberculosis.
Researchers discovered a specific code that unlocks T cell activation, preventing immune cells from attacking the body's own cells. The code is: B1, C2, A1, A2, B2, C1.
Researchers at The Wistar Institute have identified a key role for the GA733 antigen in inhibiting colorectal cancer cell invasion. The discovery has led to the development of an antibody that increases survival rates for CRC patients.
Researchers at Duke University Medical Center have developed a novel vaccine that uses RNA and dendritic cells to target cancer cells. The vaccine stimulates an immediate and sustained assault on human cells in test tube experiments, showing promise as a universal cancer vaccine.
Researchers from Rockefeller University have developed a new method to fight cancer by using dendritic cells to activate T cells. This technique offers the promise of new therapies for cancer, AIDS, and autoimmune diseases, potentially overcoming the need for designer immunotherapy.
Researchers are developing a new approach to cancer treatment called adoptive immunotherapy, which uses tumour antigens to stimulate immune cells. Tumour antigens are identified and used to sensitize T cells, which then recognize and attack cancer cells.
A new technology has been developed to address the need for Rh immune globulin, a treatment for pregnant women with Rh-Factor Incompatibility. The approach uses phage display to isolate anti-Rh antibodies from whole cells, offering a promising solution to this long-standing problem.
A new diagnostic test uses purified proteins to detect Neospora caninum, a parasite causing cattle abortions. The test has been developed by the US Department of Agriculture and is expected to be commercially available within two to three years.